Additional File 1 of TruNeo: an Integrated Pipeline Improves Personalized True Tumor Neoantigen Identification

Yuling Tang,Ye Wang,Hua Wang,Miao Li,Linmin Peng,Guochao Wei,Yixing Zhang,Li Jin,Zhibo Gao

DOI: https://doi.org/10.6084/m9.figshare.13257720

2020-01-01

Abstract:Additional file 1. Median rank of epitopes with pre-existing CD8 immune response.

What problem does this paper attempt to address?

TruNeo: an integrated pipeline improves personalized true tumor neoantigen identification

Yunxia Tang,Yu Wang,Jiaqian Wang,Miao Li,Linmin Peng,Guochao Wei,Yixing Zhang,Jin Li,Zhibo Gao

DOI: https://doi.org/10.1186/s12859-020-03869-9

IF: 3.307

2020-11-18

BMC Bioinformatics

Abstract:Abstract Background Neoantigen-based personal vaccines and adoptive T cell immunotherapy have shown high efficacy as a cancer treatment in clinical trials. Algorithms for the accurate prediction of neoantigens have played a pivotal role in such studies. Some existing bioinformatics methods, such as MHCflurry and NetMHCpan, identify neoantigens mainly through the prediction of peptide-MHC binding affinity. However, the predictive accuracy of immunogenicity of these methods has been shown to be low. Thus, a ranking algorithm to select highly immunogenic neoantigens of patients is needed urgently in research and clinical practice. Results We develop TruNeo, an integrated computational pipeline to identify and select highly immunogenic neoantigens based on multiple biological processes. The performance of TruNeo and other algorithms were compared based on data from published literature as well as raw data from a lung cancer patient. Recall rate of immunogenic ones among the top 10-ranked neoantigens were compared based on the published combined data set. Recall rate of TruNeo was 52.63%, which was 2.5 times higher than that predicted by MHCflurry (21.05%), and 2 times higher than NetMHCpan 4 (26.32%). Furthermore, the positive rate of top 10-ranked neoantigens for the lung cancer patient were compared, showing a 50% positive rate identified by TruNeo, which was 2.5 times higher than that predicted by MHCflurry (20%). Conclusions TruNeo, which considers multiple biological processes rather than peptide-MHC binding affinity prediction only, provides prioritization of candidate neoantigens with high immunogenicity for neoantigen-targeting personalized immunotherapies.

biochemical research methods,biotechnology & applied microbiology,mathematical & computational biology
NeoTCR: an immunoinformatic database of experimentally-supported functional neoantigen-specific TCR sequences

Weijun Zhou,Wenting Xiang,Jinyi Yu,Zhihan Ruan,Yichen Pan,Kankan Wang,Jian Liu

DOI: https://doi.org/10.1093/gpbjnl/qzae010

2024-02-03

Abstract:Abstract Neoantigen-based immunotherapy has demonstrated long-lasting antitumor activity. The recognition of neoantigens by T cell receptors (TCRs) is considered a trigger for antitumor responses. Due to the overwhelming number of TCR repertoires in the human genome, pinpointing neoantigen-specific TCRs is a formidable challenge. Recent studies have identified a number of functional neoantigen-specific TCRs, but the corresponding information is scattered across published literature and is difficult to retrieve. To improve access to these data, we developed an immunoinformatic database (NeoTCR) containing a unified description of publicly available neoantigen-specific TCR sequences, as well as relevant information on targeted neoantigens, from experimentally supported studies across 18 cancer subtypes. A user-friendly web interface allows interactive browsing and running of complex database queries. To facilitate rapid identification of neoantigen-specific TCRs from raw sequencing data, NeoTCR offers a one-stop analysis for annotation and visualization of TCR clonotypes, discovery of existing neoantigen-specific TCRs, and exclusion of bystander viral-associated TCRs. NeoTCR represents a unique tool to expedite future studies of neoantigen-specific TCRs and the development of neoantigen-based immunotherapy. NeoTCR is available at http://neotcrdb.bioaimed.com/ and https://github.com/lyotvincent/NeoTCR.

genetics & heredity
Neoantigen Identification Strategies Enable Personalized Immunotherapy in Refractory Solid Tumors

Fangjun Chen,Zhengyun Zou,Juan Du,Shu Su,Jie Shao,Fanyan Meng,Ju Yang,Qiuping Xu,Naiqing Ding,Yang,Qin Liu,Qin Wang,Zhichen Sun,Shujuan Zhou,Shiyao Du,Jia Wei,Baorui Liu

DOI: https://doi.org/10.1172/jci99538

2019-01-01

Abstract:BACKGROUND:Recent genomic and bioinformatic technological advances have made it possible to dissect the immune response to personalized neoantigens encoded by tumor-specific mutations. However, timely and efficient identification of neoantigens is still one of the major obstacles to using personalized neoantigen-based cancer immunotherapy.METHODS:Two different pipelines of neoantigens identification were established in this study: (1) Clinical grade targeted sequencing was performed in patients with refractory solid tumor, and mutant peptides with high variant allele frequency and predicted high HLA-binding affinity were de novo synthesized. (2) An inventory-shared neoantigen peptide library of common solid tumors was constructed, and patients' hotspot mutations were matched to the neoantigen peptide library. The candidate neoepitopes were identified by recalling memory T-cell responses in vitro. Subsequently, neoantigen-loaded dendritic cell vaccines and neoantigen-reactive T cells were generated for personalized immunotherapy in six patients.RESULTS:Immunogenic neo-epitopes were recognized by autologous T cells in 3 of 4 patients who utilized the de novo synthesis mode and in 6 of 13 patients who performed shared neoantigen peptide library, respectively. A metastatic thymoma patient achieved a complete and durable response beyond 29 months after treatment. Immune-related partial response was observed in another patient with metastatic pancreatic cancer. The remaining four patients achieved the prolonged stabilization of disease with a median PFS of 8.6 months.CONCLUSIONS:The current study provided feasible pipelines for neoantigen identification. Implementing these strategies to individually tailor neoantigens could facilitate the neoantigen-based translational immunotherapy research.TRIAL REGSITRATION. ChiCTR.org ChiCTR-OIC-16010092, ChiCTR-OIC-17011275, ChiCTR-OIC-17011913; ClinicalTrials.gov NCT03171220.FUNDING:This work was funded by grants from the National Key Research and Development Program of China (Grant No. 2017YFC1308900), the National Major Projects for "Major New Drugs Innovation and Development" (Grant No.2018ZX09301048-003), the National Natural Science Foundation of China (Grant No. 81672367, 81572329, 81572601), and the Key Research and Development Program of Jiangsu Province (No. BE2017607).
Abstract 3543: TWNeoDB: A web-based database for tumor neoantigens in the Taiwanese population

Yu-Hsuan Tseng,Chia-Hsin Wu,Chia-Yu Sung,Huang Kevin Chih Yang,Mong-Hsun Tsai,Liang-Chuan Lai,Tzu-Pin Lu,K.S. Clifford Chao,Eric Y. Chuang,Chien-Yueh Lee

DOI: https://doi.org/10.1158/1538-7445.am2024-3543

IF: 11.2

2024-04-04

Cancer Research

Abstract:Tumor neoantigens are highly immunogenic. Two types of neoantigens have been reported for their ability to be shared among patients. One is a mutated tumor-specific antigen (mTSA) derived from somatic mutations in tumor cells. The other is an aberrantly expressed TSA (aeTSA), influenced by epigenetic changes or abnormal RNA splicing. Tumor neoantigens can bind with the major histocompatibility complex (MHC) and be recognized by the T cell receptor (TCR). Consequently, they can trigger the immune system to attack cancer cells. Until now, some neoantigen databases have been available, they mostly focus on the Western population and primarily contain peptides derived from mTSAs. In contrast, our database provides peptides not only from mTSA but also from aeTSA with a strong emphasis on the Taiwanese population. Initially, we obtained public sequencing raw data from the NCBI database and employed a neoantigen pipeline for analysis, identifying potential neoantigens. The data collection criteria included samples from Taiwanese individuals, with paired DNA-seq or RNA-seq from both normal and tumor tissues of the same patients. RNA sequencing datasets were utilized to identify aeTSAs and mTSAs, whereas DNA sequencing datasets served for mTSA identification. Additionally, human leukocyte antigen (HLA) genotyping was performed for every sample. The identified peptides were further compared to previously validated data available on IEDB. This data was used to develop a web-based database with several functionalities. Users can search for specific peptides and download relevant data from the website. The website also included data cross-referenced and validated with IEDB. In addition, we incorporated clinically validated peptides capable of stimulating T cells to release cytotoxins or interferons. A machine-learning-based LightGBM model was trained to predict immunogenicity for these peptides through a series of cross-validations based on random data splitting. Users can access comprehensive information on tumor-specific peptides in the online database. We collected sequencing data from 243 patients, spanning five different types of cancer. The predominant HLA genotype is HLA-A*11:01, a common allele in the Taiwanese population. Peptide characteristics, such as hydrophobicity, binding affinity, and binding stability, have been calculated and stored in the database. Notably, the LightGBM model excelled in predicting immunogenicity, achieving an AUC of 0.95 on the training dataset and 0.8 on the testing dataset. Implemented in the online database, this model allows users to forecast their own candidates. The state-of-the-art database serves as a comprehensive platform for gathering Taiwanese-specific neoantigens, contributing to the advancement of personalized cancer vaccines and immunotherapies. Citation Format: Yu-Hsuan Tseng, Chia-Hsin Wu, Chia-Yu Sung, Huang Kevin Chih Yang, Mong-Hsun Tsai, Liang-Chuan Lai, Tzu-Pin Lu, K.S. Clifford Chao, Eric Y. Chuang, Chien-Yueh Lee. TWNeoDB: A web-based database for tumor neoantigens in the Taiwanese population [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3543.

oncology
TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis.

Jingcheng Wu,Wenyi Zhao,Binbin Zhou,Zhixi Su,Xun Gu,Zhan Zhou,Shuqing Chen

DOI: https://doi.org/10.1016/j.gpb.2018.06.003

2018-01-01

Abstract:Tumor-specific neoantigens have attracted much attention since they can be used as biomarkers to predict therapeutic effects of immune checkpoint blockade therapy and as potential targets for cancer immunotherapy. In this study, we developed a comprehensive tumor-specific neoantigen database (TSNAdb v1.0), based on pan-cancer immunogenomic analyses of somatic mutation data and human leukocyte antigen (HLA) allele information for 16 tumor types with 7748 tumor samples from The Cancer Genome Atlas (TCGA) and The Cancer Immunome Atlas (TCIA). We predicted binding affinities between mutant/wild-type peptides and HLA class I molecules by NetMHCpan v2.8/v4.0, and presented detailed information of 3,707,562/1,146,961 potential neoantigens generated by somatic mutations of all tumor samples. Moreover, we employed recurrent mutations in combination with highly frequent HLA alleles to predict potential shared neoantigens across tumor patients, which would facilitate the discovery of putative targets for neoantigen-based cancer immunotherapy. TSNAdb is freely available at http://biopharm.zju.edu.cn/tsnadb.
312P Identification of Neoantigen-Specific T Cell Response and Anti-Tumour Immunity in Pancreatic Cancer

X. Du,W. Lin,X. Lyu,Y. Huang,K. He,J. Cao,L. Teng

DOI: https://doi.org/10.1016/j.annonc.2020.10.306

IF: 51.769

2020-01-01

Annals of Oncology

Abstract:Pancreatic cancer is a highly aggressive malignancy with relatively low morbidity, which is marked by insidious clinical symptoms but rapid development. The therapeutic options of PC are limited for the insensitivity of traditional chemoradiotherapies. The neoantigen-based vaccine is an emerging tumor immune therapeutic option, but limited evidence proved the efficient therapeutic response in pancreatic cancer. Whole exome sequencing and bioinformatic analysis as well as quantitative real-time PCR of our previously established human pancreatic cancer cell line were performed to identify neoantigen candidates. The Immunogenicity of prioritized neoantigens was evaluated by analyzing the INF-γ secretion of neoantigen-induced T cell. The antitumor immunity of neoantigen-specific Cytotoxic T cells was examined by the cytotoxicity assay. The commutative analysis and quantitative real-time PCR identified 13 candidate neoantigens of our previously established human pancreatic cancer cell line PDXPC1 which was confirm as a multi-drug resistant cancer cell line. 4 of 13 candidate neoantigens can be recognized by the immune system and induced strong neoantigen-specific T cell response. The cytotoxic activities mediated by neoantigen-specific T cells significantly inhibited the growth of PDXPC1 tumor cells. Noteworthily, T cells recognized 3 of 4 neoepitopes via the presentation of dendritic cells. In conclusion, the neoantigens selected by the next generation sequencing and computational algorithm can target the tumor inhibition of pancreatic cancer, which represent a new powerful approach for multidrug resistance and suggest a general strategy for personalized cancer immunotherapy in pancreatic cancer.
Recent advances of neoantigen in tumor therapy

Zhi-hao LIU,Shi-xin NI,Si-yuan HE,Shu-qing CHEN

DOI: https://doi.org/10.3969/j.issn.1005-1678.2016.12.003

2016-01-01

Abstract:As the research work went further and more detailed, a variety of new treatments compete to come out.However, it remains unclear that how the antigen works to distinguish cancer cells and normal cells.Neoantigen, which is located in the tumor cell surface of a specific antigen, its presence makes human immunotherapy into new areas which may make personalized treatment possible in the near future.Emerging data suggest that the identification of such newantigens is a major factor in clinical immunotherapy.They can form a biomarker in cancer immunotherapy to provide targets for a variety of therapeutic approaches to attack, which allows T cells to selectively enhance the immune response against this class of antigens.
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction

Daniel K. Wells,Marit M. van Buuren,Kristen K. Dang,Vanessa M. Hubbard-Lucey,Kathleen C.F. Sheehan,Katie M. Campbell,Andrew Lamb,Jeffrey P. Ward,John Sidney,Ana B. Blazquez,Andrew J. Rech,Jesse M. Zaretsky,Begonya Comin-Anduix,Alphonsus H.C. Ng,William Chour,Thomas V. Yu,Hira Rizvi,Jia M. Chen,Patrice Manning,Gabriela M. Steiner,Xengie C. Doan,The Tumor Neoantigen Selection Alliance,Aly A. Khan,Amit Lugade,Ana M. Mijalkovic Lazic,Angela A. Elizabeth Frentzen,Arbel D. Tadmor,Ariella S. Sasson,Arjun A. Rao,Baikang Pei,Barbara Schrörs,Beata Berent-Maoz,Beatriz M. Carreno,Bin Song,Bjoern Peters,Bo Li,Brandon W. Higgs,Brian J. Stevenson,Christian Iseli,Christopher A. Miller,Christopher A. Morehouse,Cornelis J.M. Melief,Cristina Puig-Saus,Daphne van Beek,David Balli,David Gfeller,David Haussler,Dirk Jäger,Eduardo Cortes,Ekaterina Esaulova,Elham Sherafat,Francisco Arcila,Gabor Bartha,Geng Liu,George Coukos,Guilhem Richard,Han Chang,Han Si,Inka Zörnig,Ioannis Xenarios,Ion Mandoiu,Irsan Kooi,James P. Conway,Jan H. Kessler,Jason A. Greenbaum,Jason F. Perera,Jason Harris,Jasreet Hundal,Jennifer M. Shelton,Jianmin Wang,Jiaqian Wang,Joel Greshock,Jonathon Blake,Joseph Szustakowski,Julia Kodysh,Juliet Forman,Lei Wei,Leo J. Lee,Lorenzo F. Fanchi,Maarten Slagter,Maren Lang,Markus Mueller,Martin Lower,Mathias Vormehr,Maxim N. Artyomov,Michael Kuziora,Michael Princiotta,Michal Bassani-Sternberg,Mignonette Macabali,Milica R. Kojicic,Naibo Yang,Nevena M. Ilic Raicevic,Nicolas Guex,Nicolas Robine,Niels Halama,Nikola M. Skundric,Ognjen S. Milicevic,Pascal Gellert,Patrick Jongeneel,Pornpimol Charoentong,Pramod K. Srivastava,Prateek Tanden,Priyanka Shah,Qiang Hu,Ravi Gupta,Richard Chen,Robert Petit,Robert Ziman,Rolf Hilker,Sachet A. Shukla,Sahar Al Seesi,Sean M. Boyle,Si Qiu,Siranush Sarkizova,Sofie Salama,Song Liu,Song Wu,Sriram Sridhar,Steven L.C. Ketelaars,Suchit Jhunjhunwala,Tatiana Shcheglova,Thierry Schuepbach,Todd H. Creasy,Veliborka Josipovic,Vladimir B. Kovacevic,Weixuan Fu,Willem-Jan Krebber,Yi-Hsiang Hsu,Yinong Sebastian,Zeynep Kosaloglu- Yalcin,Zhiqin Huang,Taha Merghoub,Justin Guinney,Adam Kolom,Cheryl Selinsky,Antoni Ribas,Matthew D. Hellmann,Nir Hacohen,Alessandro Sette,James R. Heath,Nina Bhardwaj,Fred Ramsdell,Robert D. Schreiber,Ton N. Schumacher,Pia Kvistborg,Nadine A. Defranoux

DOI: https://doi.org/10.1016/j.cell.2020.09.015

IF: 64.5

2020-10-01

Cell

Abstract:Many approaches to identify therapeutically relevant neoantigens couple tumor sequencing with bioinformatic algorithms and inferred rules of tumor epitope immunogenicity. However, there are no reference data to compare these approaches, and the parameters governing tumor epitope immunogenicity remain unclear. Here, we assembled a global consortium wherein each participant predicted immunogenic epitopes from shared tumor sequencing data. 608 epitopes were subsequently assessed for T cell binding in patient-matched samples. By integrating peptide features associated with presentation and recognition, we developed a model of tumor epitope immunogenicity that filtered out 98% of non-immunogenic peptides with a precision above 0.70. Pipelines prioritizing model features had superior performance, and pipeline alterations leveraging them improved prediction performance. These findings were validated in an independent cohort of 310 epitopes prioritized from tumor sequencing data and assessed for T cell binding. This data resource enables identification of parameters underlying effective anti-tumor immunity and is available to the research community.

cell biology,biochemistry & molecular biology
Identification and characterization of immunogenic neoantigens in colorectal cancer (CRC).

Francesca Battaglin,Andrew Elliott,Joanne Xiu,Sandra Algaze,Jingyuan Wang,Priya Jayachandran,Shivani Soni,Karam Ashouri,Alexandra Wong,Pooja Mittal,Jae Ho Lo,Lesly Torres-Gonzalez,Wu Zhang,Benjamin Adam Weinberg,Anthony F. Shields,Richard M. Goldberg,John Marshall,Emil Lou,Heinz-Josef Lenz

DOI: https://doi.org/10.1200/jco.2024.42.3_suppl.161

IF: 45.3

2024-01-20

Journal of Clinical Oncology

Abstract:161 Background: Presentation of neoantigens, short peptides derived from tumor-specific somatic mutations, by HLA molecules triggers the activation of anti-tumor immune response. Recognition of neoantigens by autologous T cells promotes sensitivity to immune checkpoint inhibitors (ICI) in mismatch repair deficient (MMRd)/microsatellite instability high (MSI-H) tumors. Neoantigen-targeted reactivity has also been reported in microsatellite stable (MSS) tumors, and neoantigens are emerging targets for tumor vaccines and adoptive cell therapy. Here, we aimed to comprehensively assess the spectrum of immunogenic neoantigens in CRC to identify new subpopulations for these therapeutic strategies. Methods: 7,053 CRC tested at Caris Life Sciences (Phoenix, AZ) with NextGen Sequencing on DNA (720-gene panel) and RNA (whole transcriptome) were analyzed. MSI status was determined by immunohistochemistry of MMR proteins and/or NGS. Immune epitope prediction was performed on translated peptide sequences harboring detected mutations using the NetMHCpan v4.0 method in the Immune Epitope Database, with HLA genotyping performed using arcasHLA. Immune/stromal cell abundance in the tumor microenvironment (TME) was estimated from RNA expression profiles using MCP-Counter. Gene expression profiles were analyzed for a transcriptional signature predictive of response to immunotherapy (T cell-inflamed signature, TIS). Results: 6,600,005 unique peptide:allele interactions were tested, of which 368,468 (5.6%) were predicted neoantigens with patient-specific HLA alleles, including 16,184 (0.25%) with high affinity. MMRd/MSI-H tumors (6.9%) had higher neoantigen load at all affinity levels compared to MSS, with 10,243 (63.3%) and 5,621 (34.7%) of the predicted high affinity neoantigens exclusively associated with MSS and MMRd/MSI-H, respectively. 32 recurrent high affinity neoantigens were identified in > 10 samples, most frequently derived from APC mutations in MSS tumors (78% of recurrent neoantigens), and from RNF43 (25%), ASXL1 (20%), and KMT2D (15%) in MMRd/MSI-H. TIS scores positively correlated with the abundance of various immune cell populations in the TME, notably cytotoxic lymphocytes (r = 0.46). Among the recurrent high affinity neoantigens, those with the highest mean TIS scores (> 90 th percentile) resulted from mutation of MSH3 (K383fs, 5.1%) and KMT2D (multiple variants, 2.8%) in MMRd/MSI-H CRC, while those in MSS CRC derived from SOX9 (multiple variants, 0.2%) and APC (multiple variants, 0.7%) but were not associated with increased mean TIS scores (~55 th percentile). Conclusions: This is one of the largest studies to investigate the landscape of immunogenic neoantigens in CRC. We were able to identify candidate recurrent peptides with high HLA binding affinity and an association with a positive TIS signature supporting the role of neoantigens as potential cancer immunotherapy targets.

oncology
NeoHunter: Flexible software for systematically detecting neoantigens from sequencing data

Tianxing Ma,Zetong Zhao,Haochen Li,Lei Wei,Xuegong Zhang

DOI: https://doi.org/10.1002/qub2.28

2024-01-24

Quantitative Biology

Abstract:Complicated molecular alterations in tumors generate various mutant peptides. Some of these mutant peptides can be presented to the cell surface and then elicit immune responses, and such mutant peptides are called neoantigens. Accurate detection of neoantigens could help to design personalized cancer vaccines. Although some computational frameworks for neoantigen detection have been proposed, most of them can only detect SNV‐ and indel‐derived neoantigens. In addition, current frameworks adopt oversimplified neoantigen prioritization strategies. These factors hinder the comprehensive and effective detection of neoantigens. We developed NeoHunter, flexible software to systematically detect and prioritize neoantigens from sequencing data in different formats. NeoHunter can detect not only SNV‐ and indel‐derived neoantigens but also gene fusion‐ and aberrant splicing‐derived neoantigens. NeoHunter supports both direct and indirect immunogenicity evaluation strategies to prioritize candidate neoantigens. These strategies utilize binding characteristics, existing biological big data, and T‐cell receptor specificity to ensure accurate detection and prioritization. We applied NeoHunter to the TESLA dataset, cohorts of melanoma and non‐small cell lung cancer patients. NeoHunter achieved high performance across the TESLA cancer patients and detected 79% (27 out of 34) of validated neoantigens in total. SNV‐ and indel‐derived neoantigens accounted for 90% of the top 100 candidate neoantigens while neoantigens from aberrant splicing accounted for 9%. Gene fusion‐derived neoantigens were detected in one patient. NeoHunter is a powerful tool to 'catch all' neoantigens and is available for free academic use on Github (XuegongLab/NeoHunter).

mathematical & computational biology
dbPepNeo2.0: A Database for Human Tumor Neoantigen Peptides From Mass Spectrometry and TCR Recognition

Manman Lu,Linfeng Xu,Xingxing Jian,Xiaoxiu Tan,Jingjing Zhao,Zhenhao Liu,Yu Zhang,Chunyu Liu,Lanming Chen,Yong Lin,Lu Xie

DOI: https://doi.org/10.3389/fimmu.2022.855976

IF: 7.3

2022-04-13

Frontiers in Immunology

Abstract:Neoantigens are widely reported to induce T-cell response and lead to tumor regression, indicating a promising potential to immunotherapy. Previously, we constructed an open-access database, i.e., dbPepNeo, providing a systematic resource for human tumor neoantigens to storage and query. In order to expand data volume and application scope, we updated dbPepNeo to version 2.0 ( http://www.biostatistics.online/dbPepNeo2 ). Here, we provide about 801 high-confidence (HC) neoantigens (increased by 170%) and 842,289 low-confidence (LC) HLA immunopeptidomes (increased by 107%). Notably, 55 class II HC neoantigens and 630 neoantigen-reactive T-cell receptor-β (TCRβ) sequences were firstly included. Besides, two new analytical tools are developed, DeepCNN-Ineo and BLASTdb. DeepCNN-Ineo predicts the immunogenicity of class I neoantigens, and BLASTdb performs local alignments to look for sequence similarities in dbPepNeo2.0. Meanwhile, the web features and interface have been greatly improved and enhanced.

immunology
Identifying and engineering TCR specificity against solid tumor neoantigens

Martin Souren Naradikian,Leslie Montero,Samantha Hall,Rukman Thota,Angela Frentzen,Milad Bahmanof,Luise Sternberg,Jerome Lane,Zeynep Kosaloglu-Yalcin,Manasa Lanka,Aaron Miller,Bjoern Peters,Ezra Cohen,Stephen Schoenberger

DOI: https://doi.org/10.4049/jimmunol.202.supp.134.1

2019-05-01

The Journal of Immunology

Abstract:Abstract Neoantigens (NeoAg) offer attractive therapeutic targets for directing a patient’s immune response to the immunogenic subset of mutations expressed exclusively by their cancer cells. Despite the specificity with which NeoAg enable tumor recognition, the majority of approaches for their identification rely on purely predictive methods such as calculating the ability of mutated peptides to bind to a patient’s set of HLA molecules. These methods have met with limited success in revealing natural targets present on tumor cells. We have developed a novel HLA-agnostic functional approach to NeoAg identification which combines genomic sequencing with bioinformatic analysis to nominate mutations for subsequent functional analysis using patient’s own T cells in an effort to identify natural responses generated under physiologic conditions. Using this, we identified a missense mutation (V205I) in the ribosomal protein RPS2 that is recognized by CD8+ T cells from tumor-infiltrating lymphocytes (TIL) of a metastatic HPV16+ Head and Neck Squamous Cell Carcinoma lesion. We then performed adoptive cellular therapy (ACT) using either unseparated TIL or those enriched for RPS2 V205I-specific CD8+ T cells and found the latter to be superior in controlling outgrowth of tumor of a PDX cell line generated from this lesion in NSG mice. Finally, we used single-cell transcriptomics to isolate the genes encoding the RPS2-specific TCR and show that it recognizes the mutated peptide bound to HLA-B*07:02. These results demonstrate that high-affinity NeoAg-specific T cell responses can be identified in cancer patients, that ACT of these cells can control tumor growth, and that the relevant TCR can be isolated for use in TCR engineering-based immunotherapy.

immunology
ProGeo-neo: a Customized Proteogenomic Workflow for Neoantigen Prediction and Selection

Yuyu Li,Guangzhi Wang,Xiaoxiu Tan,Jian Ouyang,Menghuan Zhang,Xiaofeng Song,Qi Liu,Qibin Leng,Lanming Chen,Lu Xie

DOI: https://doi.org/10.1186/s12920-020-0683-4

2020-01-01

BMC Medical Genomics

Abstract:BACKGROUND:Neoantigens can be differentially recognized by T cell receptor (TCR) as these sequences are derived from mutant proteins and are unique to the tumor. The discovery of neoantigens is the first key step for tumor-specific antigen (TSA) based immunotherapy. Based on high-throughput tumor genomic analysis, each missense mutation can potentially give rise to multiple neopeptides, resulting in a vast total number, but only a small percentage of these peptides may achieve immune-dominant status with a given major histocompatibility complex (MHC) class I allele. Specific identification of immunogenic candidate neoantigens is consequently a major challenge. Currently almost all neoantigen prediction tools are based on genomics data.RESULTS:Here we report the construction of proteogenomics prediction of neoantigen (ProGeo-neo) pipeline, which incorporates the following modules: mining tumor specific antigens from next-generation sequencing genomic and mRNA expression data, predicting the binding mutant peptides to class I MHC molecules by latest netMHCpan (v.4.0), verifying MHC-peptides by MaxQuant with mass spectrometry proteomics data searched against customized protein database, and checking potential immunogenicity of T-cell-recognization by additional screening methods. ProGeo-neo pipeline achieves proteogenomics strategy and the neopeptides identified were of much higher quality as compared to those identified using genomic data only.CONCLUSIONS:The pipeline was constructed based on the genomics and proteomics data of Jurkat leukemia cell line but is generally applicable to other solid cancer research. With massively parallel sequencing and proteomics profiling increasing, this proteogenomics workflow should be useful for neoantigen oriented research and immunotherapy.
Supplementary Methods from an Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens As Potential Immunologic and Clinical Targets in Cancer

Qing-Wen Xu,Wei Zhao,Yue Wang,Maureen A. Sartor,Dong-Mei Han,Jixin Deng,Rakesh Ponnala,Jiang-Ying Yang,Qing-Yun Zhang,Guo-Qing Liao,Yi-Mei Qu,Lu Li,Fang-Fang Liu,Hong-Mei Zhao,Yan-Hui Yin,Wei-Feng Chen,Yu Zhang,Xiao-Song Wang

DOI: https://doi.org/10.1158/0008-5472.22394712

2023-01-01

Abstract:PDF file - 179K, Includes HEPA analysis data, Calculation of DP score, and supplementary references
ProGeo-Neo v2.0: A One-Stop Software for Neoantigen Prediction and Filtering Based on the Proteogenomics Strategy

Chunyu Liu,Yu Zhang,Xingxing Jian,Xiaoxiu Tan,Manman Lu,Jian Ouyang,Zhenhao Liu,Yuyu Li,Linfeng Xu,Lanming Chen,Yong Lin,Lu Xie

DOI: https://doi.org/10.3390/genes13050783

IF: 4.141

2022-04-28

Genes

Abstract:A proteogenomics-based neoantigen prediction pipeline, namely ProGeo-neo, was previously developed by our team to predict neoantigens, allowing the identification of class-I major histocompatibility complex (MHC) binding peptides based on single-nucleotide variation (SNV) mutations. To improve it, we here present an updated pipeline, i.e., ProGeo-neo v2.0, in which a one-stop software solution was proposed to identify neoantigens based on the paired tumor-normal whole genome sequencing (WGS)/whole exome sequencing (WES) data in FASTQ format. Preferably, in ProGeo-neo v2.0, several new features are provided. In addition to the identification of MHC-I neoantigens, the new version supports the prediction of MHC class II-restricted neoantigens, i.e., peptides up to 30-mer in length. Moreover, the source of neoantigens has been expanded, allowing more candidate neoantigens to be identified, such as in-frame insertion-deletion (indels) mutations, frameshift mutations, and gene fusion analysis. In addition, we propose two more efficient screening approaches, including an in-group authentic neoantigen peptides database and two more stringent thresholds. The range of candidate peptides was effectively narrowed down to those that are more likely to elicit an immune response, providing a more meaningful reference for subsequent experimental validation. Compared to ProGeo-neo, the ProGeo-neo v2.0 performed well based on the same dataset, including updated functionality and improved accuracy.

genetics & heredity
A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy

Florian Huber,Marion Arnaud,Brian J. Stevenson,Justine Michaux,Fabrizio Benedetti,Jonathan Thevenet,Sara Bobisse,Johanna Chiffelle,Talita Gehert,Markus Müller,HuiSong Pak,Anne I. Krämer,Emma Ricart Altimiras,Julien Racle,Marie Taillandier-Coindard,Katja Muehlethaler,Aymeric Auger,Damien Saugy,Baptiste Murgues,Abdelkader Benyagoub,David Gfeller,Denarda Dangaj Laniti,Lana Kandalaft,Blanca Navarro Rodrigo,Hasna Bouchaab,Stephanie Tissot,George Coukos,Alexandre Harari,Michal Bassani-Sternberg

DOI: https://doi.org/10.1038/s41587-024-02420-y

IF: 46.9

2024-10-12

Nature Biotechnology

Abstract:The accurate identification and prioritization of antigenic peptides is crucial for the development of personalized cancer immunotherapies. Publicly available pipelines to predict clinical neoantigens do not allow direct integration of mass spectrometry immunopeptidomics data, which can uncover antigenic peptides derived from various canonical and noncanonical sources. To address this, we present an end-to-end clinical proteogenomic pipeline, called NeoDisc, that combines state-of-the-art publicly available and in-house software for immunopeptidomics, genomics and transcriptomics with in silico tools for the identification, prediction and prioritization of tumor-specific and immunogenic antigens from multiple sources, including neoantigens, viral antigens, high-confidence tumor-specific antigens and tumor-specific noncanonical antigens. We demonstrate the superiority of NeoDisc in accurately prioritizing immunogenic neoantigens over recent prioritization pipelines. We showcase the various features offered by NeoDisc that enable both rule-based and machine-learning approaches for personalized antigen discovery and neoantigen cancer vaccine design. Additionally, we demonstrate how NeoDisc's multiomics integration identifies defects in the cellular antigen presentation machinery, which influence the heterogeneous tumor antigenic landscape.

biotechnology & applied microbiology
The T Cell Receptor beta Chain Repertoire of Tumor Infiltrating Lymphocytes Improves Neoantigen Prediction and Prioritization

Thi Mong Quynh Pham,Thanh Nhan Nguyen,Bui Que Tran Nguyen,Hoang Thien Phuc Nguyen,Thi Phuong Diem Tran,Nguyen My Diem Pham,Thi Kim Cuong Ho,Dinh Viet Linh Nguyen,Huu Thinh Nguyen,Duc Huy Tran,Thanh Sang Tran,Truong-Vinh Ngoc Pham,Minh-Triet Le,Thi Tuong Vy Nguyen,Minh-Duy Phan,Hoa Giang,Hoai-Nghia Nguyen,Le Son Tran

DOI: https://doi.org/10.1101/2023.11.16.567478

2024-06-20

Abstract:In the realm of cancer immunotherapy, the meticulous selection of neoantigens plays a fundamental role in enhancing personalized treatments. Traditionally, this selection process has heavily relied on predicting the binding of peptides to human leukocyte antigens (pHLA). Nevertheless, this approach often overlooks the dynamic interaction between tumor cells and the immune system. In response to this limitation, we have developed an innovative prediction algorithm rooted in machine learning, integrating T cell receptor β chain (TCRβ) profiling data from colorectal cancer (CRC) patients for a more precise neoantigen prioritization. TCRβ sequencing was conducted to profile the TCR repertoire of tumor-infiltrating lymphocytes (TILs) from 28 CRC patients. The data unveiled both intra-tumor and inter-patient heterogeneity in the TCRβ repertoires of CRC patients, likely resulting from the stochastic utilization of V and J segments in response to neoantigens. Our novel combined model integrates pHLA binding information with pHLA-TCR binding to prioritize neoantigens, resulting in heightened specificity and sensitivity compared to models using individual features alone. The efficacy of our proposed model was corroborated through ELISpot assays on long peptides, performed on four CRC patients. These assays demonstrated that neoantigen candidates prioritized by our combined model outperformed predictions made by the established tool NetMHCpan. This comprehensive assessment underscores the significance of integrating pHLA binding with pHLA-TCR binding analysis for more effective immunotherapeutic strategies.

Biology
dbPepNeo: a manually curated database for human tumor neoantigen peptides

Xiaoxiu Tan,Daixi Li,Pengjie Huang,Xingxing Jian,Huihui Wan,Guangzhi Wang,Yuyu Li,Jian Ouyang,Yong Lin,Lu Xie

DOI: https://doi.org/10.1093/database/baaa004

2020-01-01

Database

Abstract:Abstract Neoantigens can function as actual antigens to facilitate tumor rejection, which play a crucial role in cancer immunology and immunotherapy. Emerging evidence revealed that neoantigens can be used to develop personalized, cancer-specific vaccines. To date, large numbers of immunogenomic peptides have been computationally predicted to be potential neoantigens. However, experimental validation remains the gold standard for potential clinical application. Experimentally validated neoantigens are rare and mostly appear scattered among scientific papers and various databases. Here, we constructed dbPepNeo, a specific database for human leukocyte antigen class I (HLA-I) binding neoantigen peptides based on mass spectrometry (MS) validation or immunoassay in human tumors. According to the verification methods of these neoantigens, the collection of peptides was classified as 295 high confidence, 247 medium confidence and 407 794 low confidence neoantigens, respectively. This can serve as a valuable resource to aid further screening for effective neoantigens, optimize a neoantigen prediction pipeline and study T-cell receptor (TCR) recognition. Three applications of dbPepNeo are shown. In summary, this work resulted in a platform to promote the screening and confirmation of potential neoantigens in cancer immunotherapy. Database URL: www.biostatistics.online/dbPepNeo/.
Additional File 4: of Molecular and Clinical Characterization of PTPN2 Expression from RNA-seq Data of 996 Brain Gliomas

Pengfei Wang,Hong‐Qing Cai,Chuanbao Zhang,Yan-Michael Li,Fei Liu,Jinghai Wan,Tao Jiang,Shouwei Li,Yan Chen

DOI: https://doi.org/10.6084/m9.figshare.6274562

2018-01-01

Abstract:Table S2. Significant immune response-related gene. (XLSX 17Â kb)
Personal and Shared Tumor-Antigen Prioritization in Diffuse Large B Cell Lymphoma Patients Undergoing CD19 CAR T Cell Treatment

Dimitra Karagkouni,Xanthi Lida Katopodi,Giulia Cheloni,Yuling Ma,Brodie Miles,Gayatri Tiwari,Jenny J. Kim,Mike Mattie,Jacalyn Rosenblatt,David Avigan,Ioannis Vlachos

DOI: https://doi.org/10.1182/blood-2023-190377

IF: 20.3

2023-11-28

Blood

Abstract:Backgroun d: Durable response to Axi-cel CD19 CAR T cell therapy is associated with activation and clonotypic expansion of the host T cell repertoire (Cheloni et al Blood, ASH, 2022). The characterization of the tumor microenvironment (TME) and the identification of tumor antigens associated with therapeutic efficacy is a critical area of investigation. Aim: We sought to determine the association between the host immune activation in response to tumor-associated and tumor-specific antigens and the clinical response to CAR-T cell treatment in diffuse large B cell lymphoma patients. Methods: RNAseq was performed on FFPE lymphoma samples collected before CAR T cell infusion (N=16). Patients were divided into 3 distinct cohorts: stable progressive disease at 1 month post-CAR T (non-responders, n=2), disease relapse within 6 months post-CAR T (relapsed, n=3), and on-going response lasting greater than 1 year (long-term responders, n=11). For neoantigens, mutations were retrieved following the GATK best practices for RNAseq data and annotated with Variant Effect Predictor (VEP). Tumor-specific antigens and tumor-associated antigens were detected by prioritizing 9-11mer amino acid sequences, preferentially presented by class I molecules, observed solely or primarily in tumor samples, respectively, as compared to a pool of healthy controls derived from 250 RNAseq samples, corresponding to 29 tissues (GTEx Portal). Antigen prioritization was performed following weighted scoring considering RNA expression, translation potential, peptide-MHC binding affinity, predicted immunogenicity, physicochemical properties, and clonality, in the case of neoantigens. Using deconvolution methods and canonical marker expression, we characterized the major immune cell types within the TME. Results: Higher cell proportions of lymphocytes and innate immune cells, including NK, and activated dendritic cells were observed in long-term responders, suggesting that a higher infiltration of these cell types in the tumor bed is associated with a better response to CAR T cell therapy. Notably, a positive correlation between the mutational burden and the a/b clonotypic expansion of peripheral blood cytotoxic T cell populations, detected from single-cell immunoprofiling (Cheloni et al Blood, ASH, 2022) was observed in eight long-term responders, consistent with prior studies highlighting the significance of neoantigens in eliciting robust and durable immune response against cancer cells. A high occurrence of neoantigens originating from the Titin ( TTN) gene in two long-term responders with the highest mutational burden was observed, and from ACTB and ACTG1, mutated genes associated with lymphoid cancers. A substantial enrichment of shared tumor antigens originating from retroelements was observed in long-term responders, suggesting the presence of common epitopes that drive an antigen-specific response. Conclusion: These findings shed light on the potential immunogenicity of specific neoantigens and shared antigens derived from repetitive elements, which could serve as promising targets for immunotherapeutic strategies in lymphoma patients. Understanding the tumor immune landscape and antigenic features associated with long-term response to CAR T cell therapy may pave the way for the development of personalized and effective combinatorial treatments for lymphoid cancers.

hematology

Additional File 1 of TruNeo: an Integrated Pipeline Improves Personalized True Tumor Neoantigen Identification

TruNeo: an integrated pipeline improves personalized true tumor neoantigen identification

NeoTCR: an immunoinformatic database of experimentally-supported functional neoantigen-specific TCR sequences

Neoantigen Identification Strategies Enable Personalized Immunotherapy in Refractory Solid Tumors

Abstract 3543: TWNeoDB: A web-based database for tumor neoantigens in the Taiwanese population

TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis.

312P Identification of Neoantigen-Specific T Cell Response and Anti-Tumour Immunity in Pancreatic Cancer

Recent advances of neoantigen in tumor therapy

Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction

Identification and characterization of immunogenic neoantigens in colorectal cancer (CRC).

NeoHunter: Flexible software for systematically detecting neoantigens from sequencing data

dbPepNeo2.0: A Database for Human Tumor Neoantigen Peptides From Mass Spectrometry and TCR Recognition

Identifying and engineering TCR specificity against solid tumor neoantigens

ProGeo-neo: a Customized Proteogenomic Workflow for Neoantigen Prediction and Selection

Supplementary Methods from an Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens As Potential Immunologic and Clinical Targets in Cancer

ProGeo-Neo v2.0: A One-Stop Software for Neoantigen Prediction and Filtering Based on the Proteogenomics Strategy

A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy

The T Cell Receptor beta Chain Repertoire of Tumor Infiltrating Lymphocytes Improves Neoantigen Prediction and Prioritization

dbPepNeo: a manually curated database for human tumor neoantigen peptides

Additional File 4: of Molecular and Clinical Characterization of PTPN2 Expression from RNA-seq Data of 996 Brain Gliomas

Personal and Shared Tumor-Antigen Prioritization in Diffuse Large B Cell Lymphoma Patients Undergoing CD19 CAR T Cell Treatment